If you could bring in former Amgen ($AMGN) CEO Kevin Sharer as a consultant, what would he say? Don't hire consultants--at least not when your top executives are codifying the sorts of behaviors they want to see in company leaders. Report
| Tuesday, October 20th | 1:00pm ET / 10:00am PT | Presented by: Rho
FDA's Breakthrough Therapy, Accelerated Approval, Priority Review, and Fast Track may speed product approval. In this webinar, David Shoemaker will explain the differences, describe strategies to determine which program may be right for you, and discuss FDA requirements for each. Register Now!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!